MCID: CVD001
MIFTS: 44

Covid-19

Categories: Infectious diseases

Aliases & Classifications for Covid-19

MalaCards integrated aliases for Covid-19:

Name: Covid-19 12 15
Wuhan Seafood Market Pneumonia Virus Infection 12
Wuhan Coronavirus Infection 12
2019 Novel Coronavirus 12
2019-Ncov Infection 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0080600

Summaries for Covid-19

Disease Ontology : 12 A Coronavirus infection that is characterized by fever, cough and shortness of breath and that has material basis in SARS-CoV-2.

MalaCards based summary : Covid-19, also known as wuhan seafood market pneumonia virus infection, is related to middle east respiratory syndrome and pneumonia. An important gene associated with Covid-19 is ACE2 (Angiotensin I Converting Enzyme 2), and among its related pathways/superpathways are Hematopoietic cell lineage and Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics. The drugs Eprosartan and Nicardipine have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and liver.

Related Diseases for Covid-19

Diseases related to Covid-19 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 951)
# Related Disease Score Top Affiliating Genes
1 middle east respiratory syndrome 31.0 TMPRSS2 FURIN DPP4 CTSL ACE2
2 pneumonia 30.4 IL6 CRP CD8A ACE
3 viral pneumonia 30.3 IL6 CRP CD8A ACE2
4 pericardial effusion 30.1 IL6 CRP ACE
5 pericarditis 29.9 IL6 CRP ACE
6 purpura 29.9 IL6 CRP ACE
7 exanthem 29.8 IL6 CRP CD8A ACE
8 chickenpox 29.8 IL6 CRP CD8A
9 bacterial pneumonia 29.8 IL6 CRP CD8A
10 sleep apnea 29.8 IL6 CRP ACE
11 severe acute respiratory syndrome 29.7 TMPRSS2 IL6 FURIN CTSL CRP AGTR2
12 aspiration pneumonia 29.7 IL6 CRP ACE
13 sleep disorder 29.6 IL6 CRP ACE
14 pharyngitis 29.6 IL6 CRP CD8A
15 neuroretinitis 29.5 CRP ACE
16 hypersensitivity vasculitis 29.5 IL6 CRP ACE
17 viral exanthem 29.4 CRP CD8A
18 pulmonary disease, chronic obstructive 29.4 IL6 CRP CD8A ACE
19 bronchopneumonia 29.4 IL6 CRP CD8A
20 intermediate coronary syndrome 29.4 IL6 DPP4 CRP ACE
21 acute cystitis 29.4 IL6 DPP4 CRP ACE
22 juvenile rheumatoid arthritis 29.4 IL6 IL2RA CRP
23 acute interstitial pneumonia 29.3 CRP CD8A
24 thyroid gland disease 29.3 IL6 CRP ACE
25 orchitis 29.3 IL6 CRP CD8A
26 pneumocystosis 29.3 IL6 CRP CD8A
27 iridocyclitis 29.2 IL6 CRP ACE
28 uremia 29.2 IL6 CRP ACE
29 meningoencephalitis 29.2 IL6 CRP CD8A
30 celiac disease 1 29.2 IL6 IL2RA DPP4 CRP CD8A
31 retinal artery occlusion 29.2 IL6 CRP ACE
32 stroke, ischemic 29.2 IL6 CRP AGTR2 ACE2 ACE
33 carotid artery disease 29.2 IL6 CRP ACE
34 angioedema 29.1 DPP4 AGTR2 ACE
35 pulmonary tuberculosis 29.1 IL6 IL2RA CRP
36 syphilis 29.1 IL6 CRP CD8A ACE
37 prediabetes syndrome 29.0 IL6 DPP4 CRP ACE
38 aortic aneurysm, familial abdominal, 1 29.0 IL6 CTSL CRP ACE
39 systemic scleroderma 29.0 IL6 CRP CD8A ACE
40 intestinal obstruction 29.0 IL6 CRP CD8A
41 cellulitis 29.0 IL6 CRP CD8A
42 sarcoidosis 1 29.0 IL2RA CRP CD8A ACE
43 kidney disease 28.8 IL6 DPP4 CRP AGTR2 ACE2 ACE
44 myocardial infarction 28.7 IL6 DPP4 CRP AGTR2 ACE2 ACE
45 coronavirus infectious disease 28.6 TMPRSS2 IL6 FURIN DPP4 CTSL CRP
46 pancytopenia 28.3 IL6 IL2RA CRP CD8A ACE
47 hydronephrosis 28.1 IL6 CRP AGTR2
48 pulmonary fibrosis, idiopathic 28.0 IL6 CRP CD8A AGTR2 ACE
49 hypertension, essential 26.6 IL6 FURIN DPP4 CRP CD8A AGTR2
50 nosophobia 11.3

Graphical network of the top 20 diseases related to Covid-19:



Diseases related to Covid-19

Symptoms & Phenotypes for Covid-19

Drugs & Therapeutics for Covid-19

Drugs for Covid-19 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 700)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Eprosartan Approved Phase 4 133040-01-4 5281037
2
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
3
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
4
Trandolapril Approved Phase 4 87679-37-6 5484727
5
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
6
Lisinopril Approved, Investigational Phase 4 76547-98-3, 83915-83-7 5362119
7
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
8
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
9
Felodipine Approved, Investigational Phase 4 72509-76-3 3333
10
Fosinopril Approved Phase 4 98048-97-6 55891
11
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
12
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
13
Nifedipine Approved Phase 4 21829-25-4 4485
14
Metolazone Approved Phase 4 17560-51-9 4170
15
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
16
Amlodipine Approved Phase 4 88150-42-9 2162
17
Verapamil Approved Phase 4 52-53-9 2520
18
Chlorthalidone Approved Phase 4 77-36-1 2732
19
Indapamide Approved Phase 4 26807-65-8 3702
20
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
21
Bendroflumethiazide Approved Phase 4 73-48-3 2315
22
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
23
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
24
Nitrendipine Approved, Investigational Phase 4 39562-70-4 4507
25
Clarithromycin Approved Phase 4 81103-11-9 84029
26
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
27
Bromhexine Approved Phase 4 3572-43-8
28
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
29
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
30
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
31
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
32
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
33
Ravulizumab Approved, Investigational Phase 4 1803171-55-2
34
Coal tar Approved Phase 4 8007-45-2
35
Ibuprofen Approved Phase 4 15687-27-1 3672
36
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
37
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
38
Nadroparin Approved, Investigational Phase 4
39
Protein C Approved Phase 4
40
Tazobactam Approved Phase 4 89786-04-9 123630
41
Piperacillin Approved Phase 4 66258-76-2 43672
42
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
43
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
44
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
45
Ofloxacin Approved Phase 4 82419-36-1 4583
46
Metformin Approved Phase 4 657-24-9 14219 4091
47
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
48
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
49
Sertraline Approved Phase 4 79617-96-2 68617
50
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740

Interventional clinical trials:

(show top 50) (show all 2393)
# Name Status NCT ID Phase Drugs
1 An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection Completed NCT04345276 Phase 4 Danoprevir+Ritonavir
2 An Open Clinical Trial to Evaluate Ganovo(Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection Completed NCT04291729 Phase 4 Ganovo+ritonavir+/-Interferon nebulization
3 The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial Recruiting NCT04330300 Phase 4 Thiazide or Thiazide-like diuretics;Calcium Channel Blockers;ACE inhibitor;Angiotensin receptor blocker
4 Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia Recruiting NCT04355026 Phase 4 Bromhexine Oral Tablet and/or hydroxychloroquine tablet
5 Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Recruiting NCT04394117 Phase 4 Angiotensin Receptor Blockers
6 Fluoxetine to Reduce Intubation and Death After COVID19 Infection Recruiting NCT04377308 Phase 4 Fluoxetine
7 A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment Recruiting NCT04384380 Phase 4 Hydroxychloroquine Sulfate 200 MG [Plaquenil]
8 Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection Recruiting NCT04411667 Phase 4 Octagam
9 A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting Recruiting NCT04370782 Phase 4 Hydroxychloroquine;Azithromycin;Zinc Sulfate;Doxycycline
10 Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications Recruiting NCT04331600 Phase 4 Chloroquine phosphate
11 Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial Recruiting NCT04353596 Phase 4 ACE inhibitor, angiotensin receptor blocker
12 Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19: A Cluster Based Randomized Selection Trial (IMPROVE-COVID) Recruiting NCT04367831 Phase 4 Enoxaparin Prophylactic Dose;Heparin Infusion;Heparin SC;Enoxaparin/Lovenox Intermediate Dose
13 Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19 Recruiting NCT04325061 Phase 4 Dexamethasone
14 Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial Recruiting NCT04334629 Phase 4 Ibuprofen
15 Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE Recruiting NCT04373707 Phase 4 Enoxaparin;Enoxaparin
16 A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial Recruiting NCT04414267 Phase 4
17 A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure. Recruiting NCT04326920 Phase 4 Sargramostim
18 Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome Recruiting NCT04341493 Phase 4 Nitazoxanide 500 MG;Hydroxychloroquine
19 mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R) Recruiting NCT04390464 Phase 4 Ravulizumab;Baricitinib
20 Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection Recruiting NCT04340557 Phase 4 Losartan
21 The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation Recruiting NCT04377750 Phase 4 Tocilizumab
22 Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial Recruiting NCT04405999 Phase 4 Bromhexine Hydrochloride
23 Open, Controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Cyclosporine Plus Standard Treatment vs Standard Treatment Only in Hospitalized Patients With COVID-19 Infection Recruiting NCT04392531 Phase 4 Cyclosporine;Standard treatment
24 Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide Recruiting NCT04406246 Phase 4 Nitazoxanide 500Mg Oral Tablet
25 COVID-19-associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults With COVID-19 Recruiting NCT04360824 Phase 4 Intermediate dose thromboprophylaxis;Standard of Care thromboprophylaxis
26 Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate Recruiting NCT04351191 Phase 4 Hydroxychloroquine Sulfate Regular dose;Hydroxychloroquine Sulfate Loading Dose;Chloroquine;Placebo
27 Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate Recruiting NCT04346667 Phase 4 Hydroxychloroquine Sulfate Regular dose;Hydroxychloroquine Sulfate Loading Dose;Chloroquine;Placebo
28 Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses Recruiting NCT04348370 Phase 4
29 PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease Recruiting NCT04335786 Phase 4 Valsartan (Diovan);Placebo oral tablet
30 Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Recruiting NCT02735707 Phase 4 Fixed-duration Hydrocortisone;Shock-dependent hydrocortisone;Ceftriaxone;Moxifloxacin or Levofloxacin;Piperacillin-tazobactam;Ceftaroline;Amoxicillin-clavulanate;Macrolide administered for 3-5 days;Macrolide administered for up to 14 days;Five-days oseltamivir;Ten-days oseltamivir;Lopinavir/ritonavir;Hydroxychloroquine;Hydroxychloroquine + lopinavir/ritonavir;Interferon-β1a;Anakinra;Fixed-duration higher dose Hydrocortisone;Tocilizumab;Sarilumab
31 A Post Marketing Surveillance (PMS) Study of RIXUBIS in India Active, not recruiting NCT03565237 Phase 4
32 Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease Active, not recruiting NCT04429867 Phase 4 Hydroxychloroquine;Placebo
33 A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Active, not recruiting NCT03324880 Phase 4
34 Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection Active, not recruiting NCT04316377 Phase 4 Hydroxychloroquine Sulfate
35 Reducing Hospital Admission of Elderly in SARS-CoV-2 Pandemic Via the Induction of Trained Immunity by Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial Active, not recruiting NCT04417335 Phase 4
36 A Phase 4, Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Pulmonary Sarcoidosis Active, not recruiting NCT03320070 Phase 4 Acthar Gel;Placebo
37 A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder Active, not recruiting NCT04085172 Phase 4 Guanfacine hydrochloride (SPD503);Atomoxetine hydrochloride
38 CSP #2002 - Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (VA-IMPACT) Active, not recruiting NCT02915198 Phase 4 Metformin XR;Placebo
39 An Electrophysiological Predictor of SSRI Response in Veterans With PTSD Active, not recruiting NCT04183205 Phase 4 Placebo;sertraline
40 CSP #596 - Optimal Treatment for Recurrent Clostridium Difficile Infection Active, not recruiting NCT02667418 Phase 4 Fidaxomicin;Vancomycin with Taper/Pulse;Vancomycin
41 CSP #2008 - Pentoxifylline in Diabetic Kidney Disease Active, not recruiting NCT03625648 Phase 4 Pentoxifylline;Placebo
42 An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Enrolling by invitation NCT04350671 Phase 4 Interferon Beta-1A;Lopinavir / Ritonavir;Single Dose of Hydroxychloroquine
43 Efficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir / Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Enrolling by invitation NCT04350684 Phase 4 Umifenovir;Interferon-β 1a;Lopinavir / Ritonavir;Single Dose of Hydroxychloroquine;Standards of Care
44 Nebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung Injury Enrolling by invitation NCT04397510 Phase 4 Heparin;0.9% Sodium-chloride
45 Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19 Enrolling by invitation NCT04308317 Phase 4 Tetrandrine
46 Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov). Not yet recruiting NCT04260594 Phase 4 Arbidol
47 Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes Not yet recruiting NCT04341935 Phase 4 Linagliptin;Insulin regimen
48 Prospective Study of the Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection Not yet recruiting NCT04350086 Phase 4 Treatment with Dexmedetomidine
49 The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients Not yet recruiting NCT04345887 Phase 4 Spironolactone 100mg;Placebo oral tablet
50 Randomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 Patients Not yet recruiting NCT04411446 Phase 4 Vitamin D;Placebo

Search NIH Clinical Center for Covid-19

Genetic Tests for Covid-19

Anatomical Context for Covid-19

MalaCards organs/tissues related to Covid-19:

40
Testes, Lung, Liver, Kidney, Heart, Brain, Skin

Publications for Covid-19

Articles related to Covid-19:

(show top 50) (show all 22613)
# Title Authors PMID Year
1
A letter to the editor: the impact of COVID-19 on intercalating and non-clinical medical students in the UK. 61
32449490 2020
2
The COVID-19 pandemic and international federation of medical students' association exchanges: thousands of students deprived of their clinical and research exchanges. 61
32552464 2020
3
Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2. 61
32459137 2020
4
Laboratory diagnosis of emerging human coronavirus infections - the state of the art. 61
32196430 2020
5
ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens. 61
32438868 2020
6
Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. 61
32306853 2020
7
Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. 61
32228222 2020
8
Being a front-line dentist during the Covid-19 pandemic: a literature review. 61
32341913 2020
9
COVID-19 pandemic - an African perspective. 61
32458760 2020
10
COVID-19: What implications for sexual and reproductive health and rights globally? 61
32191167 2020
11
What lies in the year ahead for medical education? A medical student's perspective during the COVID-19 pandemic. 61
32544000 2020
12
Access to later abortion in the United States during COVID-19: challenges and recommendations from providers, advocates, and researchers. 61
32460663 2020
13
The burden, admission, and outcome of COVID-19 in Africa: protocol for a systematic review and meta-analysis. 61
32538295 2020
14
Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression. 61
32476607 2020
15
A case series describing the epidemiology and clinical characteristics of COVID-19 infection in Jilin Province. 61
32441574 2020
16
Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19. 61
32338155 2020
17
What COVID-19 outbreak in Iran teaches us about virtual medical education. 61
32449487 2020
18
Diagnostic value and key features of computed tomography in Coronavirus Disease 2019. 61
32241244 2020
19
Significance of serology testing to assist timely diagnosis of SARS-CoV-2 infections: implication from a family cluster. 61
32286155 2020
20
The coronavirus pandemic - A critical discussion of a tourism research agenda. 61
32518437 2020
21
Medical students' dilemma during the Covid-19 pandemic; between the will to help and the fear of contamination. 61
32578522 2020
22
Intersectionality as a lens to the COVID-19 pandemic: implications for sexual and reproductive health in development and humanitarian contexts. 61
32366190 2020
23
Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020. 61
32562480 2020
24
Abortion in the context of COVID-19: a human rights imperative. 61
32308156 2020
25
Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. 61
32357808 2020
26
Reproductive health under COVID-19 - challenges of responding in a global crisis. 61
32441213 2020
27
Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity. 61
32403995 2020
28
SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. 61
32529952 2020
29
Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. 61
32196410 2020
30
Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents. 61
32490731 2020
31
Experimental aerosol survival of SARS-CoV-2 in artificial saliva and tissue culture media at medium and high humidity. 61
32496967 2020
32
Mathematic modeling of COVID-19 in the United States. 61
32338150 2020
33
Family medicine in times of 'COVID-19': A generalists' voice. 61
32349550 2020
34
Idle medical students review emerging COVID-19 research. 61
32441229 2020
35
Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient. 61
32342724 2020
36
Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. 61
32228226 2020
37
COVID-19: an FY1 on the frontline. 61
32340566 2020
38
COVID-19: animals, veterinary and zoonotic links. 61
32393111 2020
39
The impact of COVID-19 on the undergraduate medical curriculum. 61
32400298 2020
40
Nurse infected with Covid-19 from a provisional dengue patient. 61
32458742 2020
41
Clinical observation and management of COVID-19 patients. 61
32208840 2020
42
The impact of COVID-19 on the Neurosurgery practice in the North of Jordan. 61
32537423 2020
43
Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19. 61
32515685 2020
44
COVID-19: time for a bold new strategy for medical education. 61
32400295 2020
45
Eco-epidemiological assessment of the COVID-19 epidemic in China, January-February 2020. 61
32404043 2020
46
The different clinical characteristics of corona virus disease cases between children and their families in China - the character of children with COVID-19. 61
32208917 2020
47
The role of asymptomatic class, quarantine and isolation in the transmission of COVID-19. 61
32498655 2020
48
Clinical characteristics of foreign-imported COVID-19 cases in Shanghai, China. 61
32515651 2020
49
Patterns of IgG and IgM antibody response in COVID-19 patients. 61
32515684 2020
50
Perspectives from a webinar: COVID-19 and sexual and reproductive health and rights. 61
32354272 2020

Variations for Covid-19

Expression for Covid-19

Search GEO for disease gene expression data for Covid-19.

Pathways for Covid-19

Pathways related to Covid-19 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.13 IL6 IL2RA CD8A
2
Show member pathways
10.7 AGTR2 ACE2 ACE

GO Terms for Covid-19

Cellular components related to Covid-19 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 TMPRSS2 IL6 FURIN DPP4 CTSL CRP

Biological processes related to Covid-19 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.43 TMPRSS2 FURIN DPP4 CTSL ACE2 ACE
2 angiotensin maturation GO:0002003 9.37 ACE2 ACE
3 negative regulation of lipid storage GO:0010888 9.32 IL6 CRP
4 neutrophil mediated immunity GO:0002446 9.26 IL6 ACE
5 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.16 ACE2 ACE
6 regulation of blood vessel diameter GO:0097746 8.8 AGTR2 ACE2 ACE

Molecular functions related to Covid-19 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endopeptidase activity GO:0004175 9.5 FURIN ACE2 ACE
2 peptidase activity GO:0008233 9.43 TMPRSS2 FURIN DPP4 CTSL ACE2 ACE
3 exopeptidase activity GO:0008238 9.26 ACE2 ACE
4 peptidyl-dipeptidase activity GO:0008241 9.16 ACE2 ACE
5 dipeptidyl-peptidase activity GO:0008239 8.8 DPP4 ACE2 ACE

Sources for Covid-19

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....